The human telomerase reverse transcriptase (hTERT) promoter is known to selectively drive transgene expression in many human cancer cells expressing hTERT, the catalytic component of the telomerase ribonucleoprotein complex. We have created a conditionally replicative adenovirus where the viral E1A gene, which is required for viral replication, is under the control of the hTERT promoter (AdhTERTp-E1A). In vitro studies with AdhTERTp-E1A virus on a variety of normal and tumor cell lines have shown that viral genome replication and productive infection is primarily restricted to telomerase-positive tumor cells. Lytic replication was not observed in normal primary fibroblast and epithelial cell lines tested. In vivo administration of the virus into nude mice bearing human liver or prostate tumor xenografts produced significant tumor reduction and, in some cases, resulted in complete tumor regression. AdhTERTp-E1A virus did not actively express E1A in normal mouse liver, in contrast to a control oncolytic vector in which the CMV promoter (AdCMVp-E1A) was driving the E1A gene. In addition, AdhTERTp-E1A virus produced no apparent toxicity to the liver in systemically injected mice. The hTERT promoter-driven oncolytic virus also produced significantly less toxicity to freshly cultured human hepatocytes. These studies demonstrate that an oncolytic virus driven by the telomerase promoter can be used to effectively kill a wide variety of cancer cell types and has the potential to treat primary and metastatic cancer of diverse origins.
I
ncreased specificity of tumor cell infection, expression, and replication is vital to the generation of successful viral vectors for cancer gene therapy. Adenovirus-based vectors are thought to have great potential for use in such therapies. Initial preclinical and clinical studies were performed with recombinant, nonreplicative adenoviruses carrying genes that promote a toxic effect on rapidly dividing tumor cells of various tissue origins. 1, 2 One common strategy has been to use recombinant adenoviruses containing the herpes simplex virus thymidine kinase (HSV-TK) gene in combination with ganciclovir (GCV) treatment as a form of suicide gene therapy for solid tumors. [3] [4] [5] Several cellular genes responsible for inducing apoptosis have also been used in preclinical models of cancer. 6, 7 The success of these treatments has been limited since it is extremely difficult to ensure that the virus will transduce every cell within a solid tumor during the initial application. The use of a virotherapy, which employs a conditionally replicative adenovirus, allows the selective replication of virus in target cell types and permits subsequent rounds of viral amplification to greatly increase the antitumor effect. [8] [9] [10] One of the first examples of an oncolytic adenovirus was Onyx-015, an E1B 55 kDa gene deleted adenovirus, that was designed to replicate exclusively in p53-deleted or mutated tumor cells and has shown encouraging results in clinical trials. 11 Tissue-and tumor-specific promoters have also been incorporated in oncolytic viral vectors to drive selective expression of genes required for viral replication in tumor cells. [12] [13] [14] [15] [16] [17] [18] While this preserves the wild-type vigor of the virus and is thus a more powerful approach, the selection of the specific promoter becomes critical to the success of the therapy. The promoters most commonly used are for organ-specific genes that are usually upregulated in tumors. This has the advantage of limiting toxicity to other organ types, and the disadvantage of limiting therapeutic application to that organ specifically. These promoters are also frequently on at low levels in many normal cells throughout the organ, resulting in unwanted toxicity to healthy regions of the organ.
Telomerase is a unique DNA polymerase whose major function is to catalyze the addition of telomeric repeats, (T2AG3)n, to the ends of chromosomes to maintain chromosomal integrity. [19] [20] [21] Over 85% of human tumors upregulate the telomerase reverse transcriptase gene (hTERT), which codes for the catalytic component of the telomerase ribonucleoprotein complex. Most normal adult somatic cells are devoid of telomerase or transiently express very low levels of the enzyme. [22] [23] [24] [25] This lack of telomerase results in progressive shortening of the telomeres and ultimately results in senescence and cell death. 26, 27 The selective telomerase expression in tumor cells is largely due to transcriptional activation of the hTERT gene. 28 While the mechanisms regulating telomerase transcription are not clearly understood, multiple control elements have been identified throughout the promoter. [29] [30] [31] A number of studies have demonstrated that the hTERT promoter is very effective in driving transgene expression in tumor cells while its activity in normal cells is generally undetectable. [32] [33] [34] We have shown previously that an adenovirus vector containing the HSV-TK gene under the control of a 204 bp hTERT promoter fragment (AdhTERTp-E1A) is cytotoxic to many types of cancer cell lines in vitro when exposed to the prodrug GCV. 35 Intratumoral administration of the AdhTERTp/TK virus plus GCV treatment also inhibited 143B osteosarcoma 35 and BxPC-3 pancreatic tumor growth (Wang and Majumdar, unpublished observation) and increased survival time of the treated animals.
We have now generated a conditionally replicative adenoviral vector (AdhTERTp-E1A) in which the hTERT promoter drives the viral E1A gene, a gene that is essential for adenoviral replication and consequently lysis of infected cells. Results presented in this report show that expression of the E1A gene under the control of the hTERT promoter and subsequently viral replication was restricted to tumor cells derived from multiple tissue types. In vivo intratumoral delivery of the virus to preestablished tumors of hepatic and prostate tissues induced significant tumor reduction and, in some cases resulted in complete tumor regression. Moreover, tumor regression and survival of animals treated with the AdhTERTp-E1A virus was equivalent to that observed using another oncolytic adenovirus in which the CMV immediate-early gene promoter was used to drive the E1A gene expression. We also show that in contrast to the AdCMVp-E1A virus, the replication-conditional AdhTERTp-E1A virus induced no observable in vivo toxicity. Thus, the selective replication of AdhTERTp-E1A in tumor cells imparted by the hTERT promoter combined with its lack of toxicity can substantially improve the therapeutic index of oncolytic virotherapy for the treatment of human malignancies.
Materials and methods

Cell cultures
The following cell lines were purchased from American Type Culture Collection (ATCC, Manassas, VA) and grown in Dulbecco's modified Eagle's medium (DMEM, Gibco-BRL, Grand Island, NY) plus 10% FBS (Hyclone, Logan, UT): A549 (lung carcinoma), DU145 (prostate carcinoma), HepG2 (hepatocellular carcinoma), LOVO (colon carcinoma), PANC-1 (pancreatic carcinoma), IMR-90 (lung fibroblast), and WI-38 (lung fibroblast). Hep3B (hepatocellular carcinoma) was cultured in EMEM (Gibco-BRL, Grand Island, NY) with 10% FBS. LNCaP (prostate carcinoma) and NCI-H1299 (non-small-cell lung carcinoma) were cultured in RPMI (Gibco-BRL, Grand Island, NY) plus 10% FBS. The following cell lines were obtained from NCI and maintained in DMEM plus 10% FBS: H226 (lung carcinoma), Hs578T (breast carcinoma), MCF7 (breast carcinoma), and OVCAR3 (ovarian carcinoma). The RPE cell line, a retinal-pigmented epithelial line, was obtained from Dr L Hjemeland of University of California, Davis, while BJ, human foreskin fibroblasts, were a kind gift from Dr J Smith of UTSW, Dallas. RPE and BJ cell lines were grown in DMEM/199 medium (Gibco-BRL, Grand Island, NY) supplemented with 10% FBS. Fresh human hepatocytes were purchased from In vitro Technologies (Baltimore, MD) and maintained in hepatocyte medium (Clonetics, San Diego, CA).
Construction of oncolytic viruses
The oncolytic adenovirus plasmid was constructed by multiple ligation steps using a pBR322-based plasmid (New England Biolab, Beverly, MA) in which the Ad2ITR (1-356 nt), Ad2E1A (549-922 nt) region) and the hTERT promoter fragment (À239 to À36 nt) were cloned. The initial steps involved PCR amplification of Ad2ITR/packaging signal fragment using the in-house synthesized primers, LC1 (5 0 -GGAATTCTACGTACAT-CATCAATAATATACC-3 0 ) and LC2 (3 0 -CACTC-GAGCGGCCCTAGACAAATATTAC-5 0 ). The Ad2 ITR and the E1A regions were cloned into the EcoRI/ ClaI sites of plasmid pBR322 resulting in the shuttle plasmid pBRAd2ITR/5'E1A. The E1A promoter region spanning from 356-548 nt was not included in the construction of the plasmid vector. Next, the 204 bp hTERT promoter fragment was excised from the plasmid pGRN176 35 and was cloned into the NotI/MunI sites of pBRAd2ITR/5'E1A directly upstream of the E1A region. Additional Ad2 sequences, 922-10,680 nt, were then cloned into BamHI/ClaI site, downstream of the E1A region in the shuttle vector. The final step involved excision of Ad2ITR/hTERTp-E1A with BstBI/SnaBI and subsequent cloning into the same sites of pAd2GFP (E3-deleted) plasmid after removing the green fluorescent protein (GFP) fragment, thus yielding the final adenoviral construct. This plasmid DNA was digested with SnaBI to release the ITRs, then transfected into 293A cells for virus propagation. The AdhTERTp-E1A virus was plaque purified and expanded in A549 cells to generate a seed stock, and then amplified in 293 cells and purified through CsCl density gradient centrifugation. Viral particle concentration was determined by measuring the optical density at A260 and the infectious titer was determined by a standard TCID 50 assay.
AdCMVp-E1A virus was constructed as above with an Ad2 backbone and with insertion of the CMV immediate-early gene promoter (À524 to À9 nt) to drive the E1A gene. AdNull is a replication deficient, E1-and E3-deleted Ad2 virus purchased from Takara Biomedicals (Shiga, Japan). AdGFP is an E1-, E3-deleted Ad5 virus carrying the GFP under the control of CMV immediate-early gene promoter/enhancer, and was purchased from Q-Biogene (Montreal, Canada).
Telomeric repeat amplification protocol (TRAP) assay
A standard TRAP assay was used to measure the telomerase activity in human cell lines. 36 For visualizing the DNA ladder, 1000 and 5000 cell equivalents were analyzed. Quantitation of telomerase activity was performed as described previously by calculating the total product generated (TPG) compared to that produced in the 293 cells, which were used as positive control.
Cell viability assay
To monitor cytotoxic effects of the viral constructs, human tumor and primary cell lines were seeded at 5 Â 
Quantitative virus replication assessment
To assess viral replication, human tumor and primary cell lines were seeded at 5 Â 10 4 cells in 12 well tissue culture plates, 20-24 hours prior to infection. The cells were then infected with 5 MOI of virus in 1 ml of their respective medium, and incubated at 371C. At 4 hours postinfection, the cells were harvested and washed twice in phosphatebuffered saline (PBS) prior to being resuspended in 100 mM Tris-HCl. At 72 and 120 hours postinfection, both culture medium and cells were harvested. All cell lysates were frozen and thawed three times to release intracellular viral particles prior to performing a standard TCID 50 assay on A549 cells. The viral lysates were serially diluted 10-fold in DMEM plus 5% FBS, then the dilutions were added to 96-well tissue culture plates seeded at 1 Â 10 4 cells per well. On days 10-12, each well was scored for cytopathic effect (CPE) development and viral titer was calculated in TCID 50 units.
Nucleic acid isolation
Snap-frozen liver and tumor samples were pulverized with Kontes Disposable Pellet Pestle using disposable probes. RNA was isolated from the ground tissue using the Qiagen RNeasy kit (Qiagen, Valencia, CA) following the tissue isolation procedure with the QiaShredder (Qiagen, Valencia, CA).
Quantative real-time RNA PCR
E1A gene-specific primers and probes were designed by Primer Express (version 1.5) software (ABI, Foster City, CA). Primer sequences are: E1A forward (TTGCCGTGAGAGTTGGTGG), E1A reverse (TTGCCCAGGCTCGTTAAGC), and E1A probe (6FAM-CGCCAGGCGTGGAATGTATCGAGG-TAM). The amplicon is 71 base pairs in length. RT-PCR was performed on the ABI 7700 (ABI, Foster City, CA) under the following conditions: 1 Â RT-Master Mix (ABI, Foster City, CA), 300 nM for each primer, and 80 nM of probe, and approximately 50 ng of total RNA in nucleasefree water. The reaction was conducted under default RT-PCR conditions at 481C for 30 minutes, at 951C for 10 minutes, and 40 cycles at 951C for 15 seconds and at 601C for 1 minute.
hTERT primers and probes were obtained from Applied Biosystems (Foster City, CA) and the hTERT gene expression assay was performed according to the PDAR protocol from the manufacturer. The RT-PCR reaction was conducted under default RT-PCR conditions as described above using approximately 50 ng of total RNA for each reaction.
Relative quantitation of gene expression between multiple samples was achieved by normalization against endogenous 18S ribosomal RNA (primer and probe from ABI, Foster City, CA) using the DDC T method of quantitation provided by the manufacturer.
In vivo tumor growth studies
Hep3B hepatocellular carcinoma cells were harvested, washed twice with PBS and resuspended at 5 Â 10 7 /ml in PBS. A mixture of 100 ml of matrigel (Beckton Dickinson, San Jose, CA) together with 200 ml of Hep3B cell suspension was injected subcutaneously in the flank region of female Balb/c nude (nu/nu) mice. When the tumor volume reached an average of 300-400 mm 3 , the mice were randomized into different treatment groups for virus injection. A dose of 5 Â 10 8 TCID 50 of AdhTERTp-E1A or AdNull virus in 50 ml volume (in 10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2 mM MgCl 2 , and 5% sucrose (w/v)) was administered intratumorally for five consecutive days. In some experiments, AdCMVp-E1A virus was used as positive control. Buffer-injected tumor-bearing mice were used as negative controls.
For the LNCaP prostate cancer model, a mixture of 100 ml of matrigel and 100 ml of cell suspension (containing 1 Â 10 6 cells in PBS) was injected subcutaneously in the flank region of male Balb/c nude (nu/nu) mice. When the tumor reached an average size of 60-70 mm 3 , five consecutive daily intratumoral injections of AdhTERTp-E1A virus, or control viruses at a dose of 5 Â 10 8 TCID 50 / injection was performed. Tumor development was monitored twice weekly. Tumor size was determined employing the formula:
Animals were humanely killed when the tumor volumes reached or exceeded 1000 mm 3 (LNCaP model), or 2000 mm 3 (Hep3B model). Survival was calculated based on the number of animals remaining (with tumor size smaller than the killing limits).
In vivo toxicity study
Female Balb/c nude (nu/nu) mice were administered, intravenously, 2 Â 10 10 viral particles (VP) per mouse of AdhTERTp-E1A, AdCMVp-E1A, or AdNull virus. Animals were sacrificed 3 days or 9 days post virus injection. Liver and spleen samples were collected. Half of the liver samples from treated animals were snap-frozen and used for nucleic acids isolation, the other half of the liver, together with spleen samples, were fixed in 10% buffered formalin. Histopathological examination of the H&E-stained sections of the liver and spleen samples were performed by contract service (IDEXX Veterinary Services, Inc., Davis, CA).
Statistics
Tumor volume and serum AFP or PSA data represent mean7SD. For statistical analysis, unpaired two-tailed Student's t-tests were used; P-values o.05 were considered to be of statistical significance. A Kaplan-Meier plot was generated to present the survival data of tumorbearing mice. Subsequently, the log rank test was used to determine statistical significance between each treatment.
Results
HTERT promoter drives tumor-specific E1A expression and subsequent viral replication in telomerase-positive tumor cells
Quantitation of hTERT transcripts in various cells was determined by real-time RT-PCR and the results are presented in Figure 1a . Of the 13 tumor cell lines tested, 11 expressed high levels of hTERT mRNA, while none of the three primary human cell lines expressed detectable levels of hTERT mRNA. Consistent with the real-time RT-PCR analysis, only the tumor cells but not the primary cells were positive for telomerase activity as determined by TRAP assay (data not shown). We next assessed the hTERT promoter activity in two human tumor and two normal cell lines by infecting the cells with the AdhTERTp-E1A virus or the control AdCMVp-E1A virus as described in the Materials and methods section. As shown in Figure 1b , in the two tumor cell lines tested, both the hTERT and CMV promoters drove efficient adenoviral E1A gene expression as determined by a realtime RT-PCR assay. When removed from its genomic context and placed in an oncolytic adenovirus, expression levels from the hTERT promoter in the context of this virus were quite strong, being approximately one and a half log lower than the CMV promoter, and approximately one log higher than the wild-type adenovirus E1A promoter (wild-type data not shown). By contrast, no E1A expression was observed using the AdhTERTp-E1A virus in normal BJ and IMR-90 fibroblast cell lines, unlike that observed when the control CMV promoterdriven oncolytic virus was used (Fig 1b) .
Coculture of AdhTERTp-E1A virus with various cancer cells resulted in CPE within 3 days of virus addition, with full CPE observed by day 5 in Hep3B (hepatocellular), H1299 (lung), LNCaP (prostate), and PANC-1 (pancreatic) tumor cells (Fig 1c, upper panels) . Infection with Ad5 wild-type virus resulted in similar kinetics for both tumor and normal tumor cell lines. Extensive CPE formation with Ad5 wild-type virus was observed within days 3 and 9 for most tumor cell lines, as well as with RPE, WI-38, and IMR-90 normal human primary cells. (data not shown). Similarly, transduction with AdCMVp-E1A virus of human primary cultures (WI-38 and IMR-90 cells) and human tumor cell lines did not reveal significant differences as extensive CPE formation was noticed with normal and tumor cells within a period of 3-10 days (data not shown). In contrast, very little or no CPE was observed when normal human fibroblast and epithelial cells were infected with the AdhTERTp-E1A virus at the same MOI (Fig 1c,  lower panels) . All four normal cell lines appeared healthy until the experiment was terminated at day 20. For quantitative measurement of cell viability after exposure to AdhTERTp-E1A, MTS assay was performed as described above (Fig 1d and e) . The AdhTERTp-E1A virus was cytotoxic to all the telomerase-positive tumor cell lines, with some differences in the kinetics of cell killing between different tumor cell lines. While greater than 95% of LNCaP (Fig 1d) and Hep3B (Fig 1e) tumors were killed within 5-7 days, longer times were required with the H1299 and PANC-1 cell lines to observe comparable levels of cytotoxicity (Fig 1e) . Virtually no cytotoxicity was detected with either of the normal cell lines tested (Fig 1d) . To further confirm that AdhTERTp-E1A-mediated cytotoxicity to tumor cells was directly linked to their hTERT expression, a telomerase negative SV-40 large T antigen transformed cell line, WI38-VA13, 38 was subjected to AdhTERTp-E1A virus infection and subjected to MTS assay for determining cell viability (Fig 1e) . No AdhTERTp-E1A-mediated cytotoxicity was detected in these WI38-VA13 tumor cells, in which telomere maintenance has been attributed to the ''ALT'' pathway. 38 Taken together, these data suggest that AdhTERTp-E1A oncolytic virus-mediated cytolysis is largely restricted to human tumor cells that are positive for telomerase expression.
Reduced toxicity of AdhTERTp-E1A virus to human hepatocytes in vitro
One of the major concerns of gene therapy or virotherapy using any form of adenoviral vectors is the resulting hepatotoxicity due to a high tropism of adenoviruses for human liver. Adult human hepatocytes expressed very low level of telomerase activity as determined previously (data not shown). We anticipated that a replicative adenovirus that uses the hTERT promoter to drive E1A gene expression should proliferate minimally in human (Fig 2a) , while parallel experiments demonstrated that both viruses were equally cytotoxic to Hep3B tumor cells (Fig 2b) . The reason for the observed mild cytotoxicity of AdhTERTp-E1A virus on human hepatocytes is not clear at this time (Fig 2a) . It could be due to nonspecific cytotoxicity encountered with the use of an oncolytic virus but not with a replication-defective adenoviral construct such as AdGFP. Alternatively, it is possible that a very low percentage of weakly telomerase-positive hepatocytes, not clearly detectable by the TRAP assay, may have contributed to the mild cytotoxicity. Normal human hepatocytes obtained from two donors gave similar results. Our results suggest that the use of hTERT promoter in the context of oncolytic virotherapy can on one hand be efficacious for its cytotoxicity while the selectivity of the promoter would prevent generalized organ-specific toxicity.
Selective amplification of AdhTERTp-E1A virus in tumor cells
To determine if productive infection of AdhTERTp-E1A is predominantly restricted to tumor cells, the virus replication was determined in 10 human tumor cell lines and two primary nontransformed human cell cultures. Amplification of AdhTERTp-E1A, AdCMVp-E1A, and AdNull viruses were examined at different time points. At each of these time points, infected cells were washed and cell lysates were prepared as stocks of freshly replicated oncolytic viruses. Each of the stocks obtained from the normal and tumor cells lines were titrated on telomerasepositive A549 cells to quantitate the levels of replicating virus. The titers of infectious virus (expressed in TCID 50 / ml) from one representative experiment using Hep3B, LNCaP, IMR-90, and BJ cells are presented in Figure 3a .
In vitro replication of AdhTERTp-E1A oncolytic virus was confined to the hepatocellular carcinoma line Hep3B and the prostate cancer cell line LNCaP. Very little or no viral replication was observed in the two normal cell lines tested. A greater than 4-5 log increase in the number of infectious viral particles produced was observed in both the Hep3B and the LNCaP tumor cells in comparison to the normal cell lines. In addition, we examined the replicative ability of AdhTERTp-E1A virus in seven other telomerase-positive cell lines and one telomerase-negative cell line Hs578T (Fig 3b) . Viral production in Hs578T, an hTERT-negative breast tumor line (Fig 1a) , was comparable to the levels seen in the telomerase-negative normal cell lines (Fig 3a) . Specificity index of AdhTERTp-E1A virus in telomerase-positive lines was determined by calculating the ratio of infectious virus particle per cell between telomerase-positive and -negative cell lines. In hTERT promoter-based oncolytic virus therapy J Irving et al this experiment, by using Hs578T line as telomerase negative control, telomerase-expressing cells showed selectivity indexes of approximately 400-4000 (Fig 3b) .
Antitumor efficacy of AdhTERTp-E1A virus in vivo
To determine if intratumoral administration of hTERTpdriven oncolytic virus would result in tumor regression, Balb/c nude mice bearing Hep3B tumors were injected intratumorally with 5 Â 10 8 TCID 50 /mouse of AdhTERTp-E1A virus per day for five consecutive days, for a total dose of 2.5 Â 10 9 TCID 50 (B1.4 Â 10 11 VP)/ mouse. Pre-established Hep3B tumors averaged between 300 and 400 mm 3 at the time of the first virus administration. Two separate groups of mice with similar tumor volumes were used as negative controls; one group receiving buffer treatment while the second group received five intratumoral injections of 5 Â 10 8 TCID 50 / mouse of the replication-defective AdNull virus. Figure 4a represents one set of data from two independent experiments. Significant inhibition of Hep3B tumor growth was limited to mice that received the AdhTERTp-E1A oncolytic virus (Po.05 between AdhTERTp-E1A-and AdNull-treated groups; Po.001 between AdhTERTp-E1A-and buffer-treated groups). Significantly prolonged survival of AdhTERTp-E1A oncolytic virus treated mice was also observed (Fig 4b, Po. 05 between AdhTERTp-E1A-and AdNull-treated groups; Po.01 between AdhTERTp-E1A-and buffer-treated groups).
We also evaluated the in vivo efficacy of AdhTERTp-E1A in the LNCaP prostate cancer model. Similar to the results observed with the Hep3B tumors, intratumoral administration of the virus in LNCaP tumors resulted in reduction of tumors in about 90% of the mice with complete tumor regression in the majority of these animals (Fig 4d, Po.01 between AdhTERTp-E1A-and AdNull-treated groups; Po.05 between AdhTERTp-E1A-and buffer-treated groups). For a direct head to head comparison with the hTERTp-containing oncolytic virus, a separate group of LNCaP tumor-bearing mice were injected with an identical dose (5 Â 10 8 TCID 50 / mouse for 5 consecutive days) of AdCMVp-E1A virus (Fig 4d) . No significant difference in tumor response was observed between these two oncolytic viruses. The antitumor effect observed with the AdhTERTp-E1A oncolytic virus in the LNCaP model significantly increased the survival of the treated mice (Fig 4e, Po. 01 between AdhTERTp-E1A-treated and AdNull-or buffertreated groups). In fact, a few mice in the AdhTERTp-E1A-treated group as well as in the AdCMVp-E1A-treated groups remained tumor free for over 200 days (see below). In all, 80-90% of animals in the buffer-and the AdNull-treated groups developed large tumors and were killed before 150 days. Representative pictures of tumorfree mice after AdhTERTp-E1A oncolytic virus treatment for Hep3B (Fig 4c) and LNCaP (Fig 4f) models are shown. Pictures of tumor-bearing mice treated with AdNull virus and buffer for both models are also shown for comparison (Fig 4c and f) .
Tumor regression data obtained with the intratumoral administration of AdhTERTp-E1A and other viruses in four experiments (two for LNCaP and two for Hep3B models are summarized in Table 1 . In the Hep3B liver cancer model, tumors regressed in 12 of 17 (71%) animals treated with AdhTERTp-E1A, while seven of 10 (70%) animals receiving AdCMVp-E1A virus showed tumor regression. Similarly, 88% and 89% of tumors regressed in LNCaP prostate-cancer-bearing mice treated with AdhTERTp-E1A and AdCMVp-E1A viruses, respectively. However, it should be mentioned that complete tumor elimination for both models was observed in higher frequencies in animals that were treated with the hTERT promoter-containing oncolytic virus than in animals receiving the CMV promoter-driven virus (Table 1) . In fact, six of 17 mice in the LNCaP model and four of 17 mice in the Hep3B model that were treated with AdhTERTp-E1A virus did not have visible tumors until the time when the experiments were terminated.
Intratumoral and systemic administration of AdhTERTp-E1A virus in mice
To determine hTERT promoter activity in vivo, preestablished Hep3B tumors were injected with a total of 2.5 Â 10 9 TCID 50 (B1.4 Â 10 11 VP) of AdhTERTp-E1A hTERT promoter-based oncolytic virus therapy J Irving et al or AdCMVp-E1A (B1.3 Â 10 11 VP) virus. The same therapeutic dose of AdhTERTp-E1A and AdCMVp-E1A virus that caused regression of pre-established tumors was used. Tumor RNA samples were isolated from two mice per group, at 2 days and 9 days post virus injection, and subjected to real-time RT-PCR analysis for E1A mRNA quantitation (Fig 5) . At both time points, the relative activity of the hTERT promoter was comparable to that of the CMV promoter in all the animals tested (Fig 5a and  b) , while no E1A RNA was detected in the tumor samples treated with an equal number of an E1-, E3-deleted recombinant AdNull virus. The E1A RT-PCR data Tumors were considered to be regressed when at least three consecutive measurements indicated shrinkage of tumor volume compared to initial tumor volume immediately prior to treatment.
hTERT promoter-based oncolytic virus therapy J Irving et al correlated with the antitumor activity demonstrated by AdhTERTp-E1A virus administration in the treated animals.
To evaluate if systemic administration of AdhTERTp-E1A could generate E1A transcripts in mouse livers that may lead to oncolytic virus propagation and hepatotoxicity, we injected mice intravenously with 2 Â 10 10 VP of AdhTERTp-E1A. RNA samples from the livers were isolated at 2 and 9 days post virus administration and real-time RT-PCR analysis was performed to quantitate the E1A mRNA (Fig 5c and d, respectively) . Although relatively high levels of E1A mRNA was detected in the liver samples of mice that received AdCMVp-E1A virus, no E1A transcript was detectable in samples isolated from the livers of AdhTERTp-E1A-treated mice. At both time points, three mice were used for all groups except AdCMVp-E1A/day 9 (Fig 5d) where samples from two animals were used. Taken together, these results further confirm that the hTERT promoter is extremely specific in targeting transgene expression to tumor cells in vivo while ensuring that the transgene expression is practically absent in the liver.
Histopathological examination of liver (Fig 6) and spleen samples (data not shown) from mice receiving systemic administration of AdhTERTp-E1A virus revealed no abnormalities at both 3 and 9 days post viral injection. In contrast, liver samples from all three mice at 3 days post AdCMVp-E1A virus administration showed However, these studies demonstrate that the AdhTERTp-E1A virus showed no toxicity following systemic delivery compared to CMVp-driven oncolytic virus infusion.
Discussion
The studies presented in this report provided preclinical data supporting the use of the hTERT promoter for oncolytic virotherapy for cancer treatment. Our results demonstrate that (a) the minimal 204 bp hTERT promoter has high enough transcriptional activity to drive the E1A gene transcription for adenoviral replication, (b) the promoter is selective in enabling the viral replication in tumor cells causing significant tumor regression including complete elimination, and (c) the AdhTERTp-E1A virus showed very little toxicity towards human hepatocytes. Transcriptional upregulation of the hTERT catalytic unit gene expression has been observed with greater than 90% of human cancers. 25, 39 This ubiquitous expression in tumors has made telomerase a very attractive target for several types of therapeutic modalities for cancer including immunotherapy, [40] [41] [42] [43] gene therapy [32] [33] [34] [35] and, as described in this report, oncolytic virotherapy. We and others have demonstrated the safety and efficacy of intratumoral delivery of replication-deficient, recombinant adenoviruses in which the hTERT promoter was used to drive either proapoptotic genes [32] [33] [34] or HSV-TK gene in combination with GCV. 35 Our results on the strength and tumor selectivity of the hTERT promoter in the oncolytic virus are consistent with those from earlier studies.
Our results suggest that the core hTERT promoter is relatively strong in initiating and sustaining the replication of the virus in various telomerase-positive cancer cells, but not in the telomerase-negative WI38/VA13 cells, thus confirming that the specificity of the virus is correlated with telomerase expression. While we have observed some differences in the kinetics of AdhTERTp-E1A virus-mediated cytolysis in various cancer cell lines examined, this does not appear to correlate with the levels of hTERT mRNA or telomerase activity present in those tumor cells (data not shown). We have observed wide variability in the transduction frequency of these cell lines relative to one another, and it is possible that differences in the surface expression of CAR or a-integrin receptors on different tumor cell lines might account for the differential kinetics observed.
To enhance the efficacy and reduce general toxicity, a number of tissue-specific promoters have been used to restrict the expression of therapeutic genes to tumor cells of various tissue types. In two instances, selectively replicating oncolytic viruses have been constructed using the a-fetoprotein 14 and prostate-specific antigen 12 promoters to drive the adenoviral E1A gene expression in hepatocellular and prostate cancer cell lines, respectively. Further studies performed using systemic delivery of a bone matrix protein osteocalcin promoter-driven oncolytic virus showed inhibition of pre-established metastatic prostate cancer in the skeleton of SCID/Bg mice. 17 Despite some success in both in vitro and in vivo studies, most of these tissue specific promoters are not entirely selective for tumor cells and have weaker transcriptional activity than viral promoters. More importantly, these promoters are generally active in one, or at most, a few particular tissue types and cannot be used as a pan-tumor specific promoter. Recently, using the E2F-1 promoter, which is activated/upregulated in human tumors with defective retinoblastoma (Rb)-mediated cell cycle pathway, several groups have constructed oncolytic adenoviral vectors where the E1A viral gene is placed under the control of E2F-1 promoter. [44] [45] [46] In vitro and in vivo studies using these vectors showed tumor-cell selectivity and significant antitumor activity in several different human tumor xenografts models.
The data presented here demonstrates that the hTERT promoter-driven adenoviral agent could mediate tumor regression in many different types of cancers, while not eliciting the generalized toxicity often seen with viral promoters. 47 Despite approximately equivalent levels of E1A mRNA generated from the hTERT and the CMV promoters in tumor cells after intratumoral administration, systemic delivery of AdhTERTp-E1A virus resulted in no observable E1A gene transcription in the liver samples (Fig 5c & d) . While this could be explained by an inability of the human promoter to drive transgene expression in mouse tissues, recent publications have shown that the hTERT promoter was highly active in mouse tumor cell lines but not in normal murine cells. 48, 49 Similarly, we observed that AdhTERTp-E1A virus transduction of telomerase-expressing murine cancer cell lines B10.2 and C57 at MOI of 100 or higher resulted in significant killing of both cell types (Wang and Majumdar, unpublished observation). Normal histopathology was observed in liver and spleen samples of mice after systemic administration of AdhTERTp-E1A virus in contrast to the pronounced morphological abnormalities detected in the liver and spleen samples of mice treated with AdCMVp-E1A construct (Fig 6 and data not  shown) . While greater than 70% of primary adult human hepatocytes succumbed to AdCMVp-E1A-mediated cytolysis, we observed greatly reduced cytotoxicity with the AdhTERTp-E1A virus (Fig 2) . Collectively, these data show remarkable specificity, efficacy, and safety of AdhTERTp-E1A oncolytic virus imparted by the hTERT promoter fragment used in these experiments.
Although lack of telomerase gene expression or the telomerase activity is reported with most adult human tissue, transient activation of telomerase gene has been detected in bone marrow CD34 þ as well as other progenitor cell types. 22, 23 Using replication-deficient adenoviral vectors, direct comparison of hTERTp and CMVp-driven Lac-Z expression in human CD34 þ cells hTERT promoter-based oncolytic virus therapy J Irving et al showed that the Ad/hTERTp-lacZ vector was 100-fold less active than the CMV vector in these bone marrow progenitor cell population. 48 Moreover, it is known that stem cells are poorly transduced by adenoviral vectors. These data suggest that the hTERT promoter-driven oncolytic virus may not be toxic to the human bone marrow stem cells. However, further studies using human bone marrow and other organ-specific stem cells as well as germ cells (telomerase positive) are required to determine the susceptibility of these cells to hTERT promoter-driven oncolytic virus-mediated toxicity. Such safety and toxicity studies will be extremely critical before hTERT promoterdriven oncolytic viral therapy is used in clinical trials for cancer therapy.
We have created a novel oncolytic virus that selectively replicates in a much broader range of tumor cells than any shown previously but which is inactive in primary somatic cells. Our data demonstrate that the hTERT promoter is strong enough to drive oncolytic adenoviral replication in a wide variety of tumor cells, and that this replication culminates in tumor regression. Our study confirms and extends the results of Wirth et al 50 and of Huang et al 51 that appeared as this manuscript was being reviewed. Together, these results suggest that the use of hTERT promoter in the context of oncolytic virotherapy can on one hand be efficacious for killing tumor cells while the selectivity of the promoter would prevent generalized organ-specific toxicity, thus providing a safe oncolytic virotherapy for the treatment of cancer.
